Abstracto
Purpose of review
Liver transplantation is the gold standard for the treatment of end-stage liver disease. Sin embargo, a shortage of donor organs, alto costo, and surgical complications limit the use of this treatment. Cellular therapies using hepatocytes, células madre hematopoyéticas, células mononucleares de la médula ósea, y células madre mesenquimales (MSC) are being investigated as alternative treatments to liver transplantation. The purpose of this review is to describe studies using MSC transplantation for liver diseases based on the reported literature and to discuss prospective research designed to improve the efficacy of MSC therapy.
Recent findings
MSCs have several properties that show potential to regenerate injured tissues or organs, such as homing, transdiferenciación, inmunosupresión, and cellular protective capacity. Además, MSCs can be noninvasively isolated from various tissues and expandedex vivo in sufficient numbers for clinical evaluation.
Resumen
Actualmente, there is no approved MSC therapy for the treatment of liver disease. Sin embargo, MSC therapy is considered a promising alternative treatment for end-stage liver diseases and is reported to improve liver function safely with no side effects. Further robust preclinical and clinical studies will be needed to improve the therapeutic efficacy of MSC transplantation.
Interesado en saber si los programas clínicos actuales, desarrollos de investigacion, o enfoques terapéuticos emergentes pueden ser relevantes para su situación?
Información educativa y de investigación únicamente.. Las decisiones médicas individuales deben tomarse en consulta con profesionales sanitarios cualificados..
